Introduction. Lactoferrin is a biologically active substance, a natural glycoprotein from the group of iron-containing proteins, transferrin. This article is devoted to a review of the literature data on the properties and prospects for the use of lactoferrin in medicine and veterinary medicine.Text. The problem of widespread use of lactoferrin is the need to use a large volume of raw materials, the difficulty of extracting it from agricultural raw materials and subsequent purification. In this view, at present, it is very promising to use transgenic animals to obtain such a valuable compound in the required volume. Discovered in 1939 in cow's milk, lactoferrin exhibits a wide spectrum of biological activity, new properties of this protein are constantly being established. The most studied are the immunomodulatory effects, anti-inflammatory, antimicrobial, antiviral, antifungal activities of lactoferrin, and the search for the possibility of using this compound for the treatment and prevention of the new coronavirus infection SARS-CoV-2, as well as for the prevention of postCOVID complications, has begun. In recent years, the antitumor activity of lactoferrin has been actively studied, as well as the prospects for its use as a biomarker for early diagnosis of neurodegenerative diseases. Lactoferrin can play a special role in the delivery of drugs to target organs, as well as in the manufacture of functional food products and various drugs for both humans and animals.Conclusion. Thus, the performed theoretical study and the data obtained on a wide spectrum of biological activity of lactoferrin confirm the prospects and expediency of the development of formulations and technology of drugs, functional food products, veterinary drugs and animal products based on lactoferrin.
10 December 2011 in Bulletin of Experimental Biology and Medicine
Objective. Organic solvents, which often have toxic and/or carcinogenic properties, are used at all stages of the production of pharmaceutical substances - synthesis, isolation and purification - and are not completely removed after the completion of the technological process. The presence of even extremely small amounts of such compounds in medicines can be dangerous for patients. The article presents the results of the development of a method for determining the content of residual organic solvents (ROS) - ethanol, toluene and dimethylformamide - in a new active pharmaceutical ingredient (API) 3-(1H-benzimidazol-2-yl)-1,2,2-trimethylcyclopentane-carboxylic acid by gas chromatography. Materials and methods. Static vapor phase analysis was used to identify and to quantify residual organic solvents. It was determined by the internal standard method using a Shimadzu GC-2014ATF/SPL gas chromatograph with an AOC-6000Plus autosampler; PID detection. Isobutyl alcohol was used as an internal standard. Results. The developed method was used to determine the content of residual organic solvents in the validation series of the new pharmaceutical substance 3-(1H-benzimidazol-2-yl)-1,2,2-trimethylcyclopentane-carboxylic acid. The method was validated in accordance with the requirements of the State Pharmacopoeia of the Russian Federation. Conclusion. The developed method is suitable for further use in quality control in the production of 3-(1H-benzimidazol-2-yl)-1,2,2-trimethylcyclopentane-carboxylic acid.
Репродуктивное здоровье женского населения России все чаще страдает от гинекологических заболеваний. Воспалительные заболевания органов малого таза являются доминирующими в этой области. Среди заболеваний данной группы выделяется вульвит и вульвовагинит. Патологии опасны своими осложнениями, которые могут привести к таким непоправимым последствиям как бесплодие. Анализ ассортимента российского фармацевтического рынка лекарственных препаратов для терапии вульвитов показал, что наиболее часто используются антибактериальные препараты и антисептики, 33 % и 17 % соответственно. Анализ лекарственных форм выявил, что мягкие лекарственные формы занимают первое место и составляют 47 % от общего числа лекарственных препаратов. Лидерами в данной группе являются суппозитории с долей рынка 87 %, в том числе вагинальных - 62 %. Среди твердых лекарственных форм, которые составляют 33 % от общего количества лекарственных препаратов, наибольшую долю занимают таблетки для внутреннего применения и таблетки вагинальные, в сумме составляющие 48 %. Жидкие лекарственные формы составляют 16 %, внутри группы лидерами являются растворы для внутреннего, наружного и местного применения - 74 %. Лекарственное растительное сырье для терапии вульвитов и вульвовагинитов представлено сборами, составляющие 4% от общей доли рынка лекарственных...
8 May 2026 in Regulatory Research and Medicine Evaluation
INRODUCTION . Biowaiver procedure based on the biopharmaceutics classification system (BCS) is widely used in regulatory practice when assessing the bioequivalence of generic medicinal products (GMPs). The use of the biowaiver is aimed at reducing the rate of in vivo studies while maintaining the requirements for GMP quality, safety, and efficacy. Over the recent years, additional analytical and modeling tools used in bioequivalence assessment have been actively discussed in the scientific literature. This requires a clear distinction between regulatory requirements and research approaches, including in vitro / in vivo correlations (IVIVC), physiologically based pharmacokinetic (PBPK) modeling, and artificial intelligence (AI) algorithms. AIM . This study aimed to compare the existing regulatory approaches to the application of the BCS-based biowaiver procedure, with an emphasis on current requirements used to assess GMP bioequivalence. DISCUSSION . In all considered regulatory systems, the use of the biowaiver procedure is limited to active pharmaceutical ingredients (APIs), BCS classes I and III, with strict adherence to solubility criteria and comparability of dissolution profiles. The division of Class II into subclasses IIa and IIb is not stipulated in any official guidelines and is used exclusively in the scientific literature for the research purposes. It has been established that IVIVC, PBPK models, and AI technologies are considered by regulatory authorities as supporting scientific tools and do not have independent status as an evidence base used to renounce the use of in vivo studies. CONCLUSIONS . The findings confirm the lack of fundamental regulatory differences between approaches to the biowaiver application. Proposals for expanding biowaiver practice identified in the references relate to scientific controversy without reflecting current regulatory practice. The work forms a methodologically correct basis for the interpretation of regulatory requirements and further research in the area of biopharmaceutical GMPs evaluation.
1 January 2021 in Achievements of Science and Technology in Agro-Industrial Complex